Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics (BEAM 2.15%), executed an open-market sale of 6,198 shares valued at approximately $216,933 on Jan. 22, 2026, as disclosed in a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 6,198 |
| Transaction value | ~$216,933.10 |
| Post-transaction shares (direct) | 34,813 |
| Post-transaction value (direct ownership) | ~$1,192,693.38 |
Transaction value based on SEC Form 4 weighted average purchase price ($35.00); post-transaction value based on Jan. 22, 2026 trade-date close ($34.26)
Key questions
- How significant was the sale relative to Bethany Cavanagh's holdings?
The 6,198 shares sold represented 15.11% of her direct holdings at the time, a larger proportion than her recent median sell transactions, indicating a material reduction in exposure. - Was this transaction part of a Rule 10b5-1 trading plan?
Yes, the shares sold were part of a Rule 10b5-1 trading plan, an investment strategy often permitted by companies that allows insiders to arrange for their shares to be sold in advance.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $55.70 million |
| Net income (TTM) | -$414.64 million |
| Employees | 510 |
| *1-year price change | 6.6% |
* 1-year price change calculated as of Jan. 31, 2026.
Company snapshot
Beam Therapeutics is a biotechnology company specializing in the research, development, and commercialization of gene editing therapies. Its medicines also target leukemia and sickle cell disease.
What this transaction means for investors
On Jan. 11, 2026, Beam Therapeutics announced its strategic priorities for 2026, which include advancing its genetic medicines and moving its products beyond clinical trials into distribution. The Food and Drug Administration (FDA) has already expressed alignment with one of its leading medicine candidates, and it has more potential solutions that it aims to advance through clinical trials and get approval by the end of the year.
The company expects that with the strong support and existing reserves it possesses, it has enough cash runway to operate into 2029.
Having gone public only five years ago, the company is still working its way to get out of operating with negative net margins. The stock increased approximately 11% in 2025, and there was very little price change as January 2026 ended. If investors are interested in BEAM shares for the long term, they should monitor the company’s medicines' progress throughout the year.
